Annals of Surgical Oncology

, Volume 18, Supplement 3, pp 316–316 | Cite as

Don’t Worry, We Have a New Weapon Against Cancer!

  • Mesut Tez
  • Selda Tez
  • Mahmut Koç
Translational Research and Biomarkers


Melanoma Optimal Form Ablative Therapy Cancer Biology Chemotherapy Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

To the Editors:

We read the editorial article by Tyler with great interest. We agree with the author that the delivery of regional chemotherapy to an isolated limb continues to be an important treatment for patients with in-transit melanoma of the extremity. While the optimal form of treatment for these individuals remains to be determined, there are multiple strategies and therapies currently being explored that have the potential to improve response to therapy.1

In the 21th century we have a new miracle weapon against cancer: “nanomedicine.”

Nanomedicine is the application of nanotechnology to medicine and is based on three mutually overlapping and progressively more powerful molecular technologies. Nanotechnology is increasingly finding use in the management of cancer. Nanoscale devices have impacted cancer biology at three levels: early detection using, for example, nanocantilevers or nanoparticles; tumor imaging using radiocontrast nanoparticles or quantum dots; and drug delivery using nanovectors and hybrid nanoparticles.2

Nanoparticles can deliver chemotherapy drugs directly to tumor cells and then emit a signal after the cells are destroyed. According to the work done in 2004 at the Center for Biological Nanotechnology of the University of Michigan, drugs delivered this way are 100 times more potent than standard therapies. Metal nanoshells belong to a class of nanoparticles with tunable optical resonances that have been used for thermal ablative therapy for cancer. Nanoshells placed at depth in tissues can be used to deliver a therapeutic dose of heat by using moderately low exposures of extracorporeally applied near-infrared. Nanoshells may be combined with targeting proteins (proteins specific for the malignant melanoma) and used to ablate target cells. This procedure can result in the obliteration of solid tumors or possibly metastases not otherwise observable by the oncologist. In addition, nanoshells can be utilized to reduce angiogenesis present in cancer. Experiments in animals in vitro and in tissue demonstrate that specific cells (e.g., cancer cells) can be targeted and destroyed.3

In conclusion, nanotechnology clearly holds immense potential for targeting cancer and we believe that the next few years are likely to see an increasing number of nanotechnology-based therapeutics and diagnostics reaching the clinic.


  1. 1.
    Tyler D. Regional therapeutic strategies in melanoma: not just local disease control, but an opportunity to develop novel therapeutic strategies with potential implications for systemic therapy. Ann Surg Oncol. 2008;11:2987–90.CrossRefGoogle Scholar
  2. 2.
    Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007;96:1315–9.PubMedGoogle Scholar
  3. 3.
    Jain KK. The handbook of nanomedicine. 1st ed. NJ: Humana; 2008.Google Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  1. 1.Fifth Surgery ClinicAnkara Numune HospitalAnkaraTurkey
  2. 2.Department of Radiology29 Mayıs HospitalAnkaraTurkey

Personalised recommendations